Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Mediastinal Neoplasms

In brief

The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of topotecan and docetaxel.

Key facts

Study ID

NCT00315211

Run by

Aultman Health Foundation

People needed

7

Starts

2004-11-01

Expected to finish

2007-11-08

Last updated by the study team

2018-08-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Recurred greater than 90 days after initial treatment
• At least 1 measurable lesion
• Only 1 prior chemotherapy
• Must be over 18 years of age
• ECOG performance status of 0 - 2
• Adequate hematologic, renal, and hepatic function

You may not qualify if…

• No prior use of topotecan, docetaxel, or irinotecan
• No symptomatic brain metastases
• History of cardiac arrhythmias, congestive heart failure, stroke, or embolic events
• No prior investigational agents within 1 month prior
• Lung cancer of mixed histology
• Known uncontrolled seizure disorders

Where it is running

• Aultman Hospital — Canton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.